Spastic conditions of the gastrointestinal tract, irritable bowel syndrome- Biliary colics and spastic conditions of the biliary tract: Cholecystolithiasis, cholecystitis, cholangitis. Renal colics and spastic conditions of the urogenital tract: Nephrolithiasis, ureterolithiasis, pyelitis, cystitis. Spastic conditions of the uterus: Dysmenorrhea, imminent abortion, uterine tetanus.
soquinolone; Antispasmodic Agent
Drotaverine HCl is a new potent synthetic antispasmodic drug which is readily absorbed from the intestine. Like papaverine, it acts directly on the smooth muscle fibers exceeding however, the antispasmodic effect of the standard preparations. Drotaverine HCl is characterized by its rapid onset of actions which has advantage in cases of acute painful spastic conditions. In addition to its spasmolytic and vasodilatory actions, Drotaverine HCl elicits a selective blockage of cardiac beta-receptors.
Oral- Adults: 1 to 2 tablets, 3 times daily Children (over 6 years): 1/2 to 1 tablet, 1-2 times daily. Children (1-6 years): 1/4 to 1/2 tablet, 1-2 times daily. Injection- Adults: 1 to 2 ampoules, intramuscularly or subcutaneously, 1-3 times daily. For the management of acute stone colics: 1 or 2 ampoules by slow intravenous injection.
May attenuate the action of levodopa. Concurrent use of analgesics, antimuscarinics or benzodiazepines. Additive beneficial effect with concurrent use of analgesics, antimuscarinics or benzodiazepines.
Drotaverine is contraindicated in patients with known hypersensitivity to the products and its constituents. Caution should be taken for patients suffering from liver and kidney disease.
The common side effects are headache, dizziness, rhinitis, sinusitis, gastrointestinal upset, nausea, pharyngitis, edema and fatigue.
As with most drugs, the use of Drotaverine Hydrochloride should be avoided during pregnancy and lactation unless essential.
To be dispensed only by or on the prescription of a registered physician. Keep out of reach of children. Keep in a cool, dry place.